A recent study indicates that people who come off popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle plans.
Findings released in a leading health publication points out that while overweight people frequently drop a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users buying these drugs should be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting weight in about one and a half years.
Weighing Treatments
The study, which looked at 37 of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
Scientists note that people who shed pounds through dieting generally have a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Doctors suggest the mode of action of the injections accounts for the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the significant potential of weight regain, the therapy might need to be ongoing.
This view is supported by pharmaceutical companies, who state that the findings "underscore the persistent nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have discontinued the medication describe a sudden return of hunger.
"I experienced a switch activating and I was suddenly ravenous," said one woman.
This difficulty is exacerbated if individuals have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Adoption
Figures show that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is more common among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while these medications are powerful tools for shedding pounds, they are not a standalone fix and lasting health benefits hinges on integrated lifestyle management.
